Deka Bank Deutsche Girozentrale Biomarin Pharmaceutical Inc Transaction History

Deka Bank Deutsche Girozentrale

$53.9 Billion
Q3 2024

A detailed history of Deka Bank Deutsche Girozentrale transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 280,330 shares of BMRN stock, worth $18.7 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

280,330

Previous 281,091 0.27%

Holding current value

$18.7 Million

Previous $23.5 Million 16.33%

% of portfolio

0.04%

Previous 0.04%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	SELL	$69.02 - $93.84 $52,524 - $71,412	-761 Reduced 0.27%	280,330 $19.7 Million
Q2 2024 Aug 08, 2024	BUY	$74.43 - $92.22 $68,475 - $84,842	920 Added 0.33%	281,091 $23.5 Million
Q1 2024 Apr 24, 2024	SELL	$83.81 - $99.0 $984,432 - $1.16 Million	-11,746 Reduced 4.02%	280,171 $24.7 Million
Q4 2023 Jan 24, 2024	SELL	$76.22 - $98.51 $493,753 - $638,147	-6,478 Reduced 2.17%	291,917 $28.3 Million
Q3 2023 Nov 13, 2023	SELL	$85.07 - $94.48 $1.72 Million - $1.91 Million	-20,230 Reduced 6.35%	298,395 $26.6 Million
Q2 2023 Jul 25, 2023	SELL	$86.68 - $100.3 $2.01 Million - $2.33 Million	-23,246 Reduced 6.8%	318,625 $28.6 Million
Q1 2023 Apr 24, 2023	BUY	$87.74 - $117.27 $3.97 Million - $5.31 Million	45,304 Added 15.28%	341,871 $32.8 Million
Q4 2022 Feb 01, 2023	BUY	$80.93 - $108.63 $589,170 - $790,826	7,280 Added 2.52%	296,567 $30.3 Million
Q3 2022 Nov 02, 2022	BUY	$82.16 - $96.94 $308,100 - $363,525	3,750 Added 1.31%	289,287 $24.5 Million
Q2 2022 Aug 03, 2022	BUY	$71.48 - $86.85 $2.2 Million - $2.68 Million	30,804 Added 12.09%	285,537 $23.8 Million
Q1 2022 Apr 28, 2022	SELL	$74.28 - $92.69 $425,995 - $531,577	-5,735 Reduced 2.2%	254,733 $19.9 Million
Q4 2021 Feb 02, 2022	SELL	$71.72 - $91.47 $2.15 Million - $2.75 Million	-30,034 Reduced 10.34%	260,468 $23.3 Million
Q3 2021 Oct 22, 2021	BUY	$74.77 - $85.47 $1.07 Million - $1.23 Million	14,333 Added 5.19%	290,502 $22.3 Million
Q2 2021 Aug 05, 2021	BUY	$75.51 - $84.79 $184,017 - $206,633	2,437 Added 0.89%	276,169 $22.9 Million
Q1 2021 Apr 28, 2021	BUY	$74.73 - $90.69 $1.35 Million - $1.64 Million	18,131 Added 7.09%	273,732 $20.5 Million
Q4 2020 Mar 12, 2021	BUY	$72.61 - $90.2 $249,560 - $310,017	3,437 Added 1.36%	255,601 $22.1 Million
Q3 2020 Oct 29, 2020	BUY	$71.87 - $131.03 $9.15 Million - $16.7 Million	127,295 Added 101.94%	252,164 $18.9 Million
Q2 2020 Aug 04, 2020	SELL	$79.55 - $124.22 $45,502 - $71,053	-572 Reduced 0.46%	124,869 $15.2 Million
Q1 2020 May 14, 2020	SELL	$71.37 - $96.85 $1.04 Million - $1.41 Million	-14,545 Reduced 10.39%	125,441 $10.2 Million
Q4 2019 Feb 04, 2020	SELL	$64.27 - $86.37 $12.3 Million - $16.5 Million	-191,097 Reduced 57.72%	139,986 $11.9 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $8.58 Million - $10.8 Million	-127,341 Reduced 27.78%	331,083 $22.6 Million
Q2 2019 Aug 01, 2019	BUY	$80.35 - $93.9 $30.2 Million - $35.3 Million	375,760 Added 454.56%	458,424 $38.6 Million
Q1 2019 May 10, 2019	SELL	$84.2 - $98.62 $7.35 Million - $8.61 Million	-87,349 Reduced 51.38%	82,664 $8.29 Million
Q4 2018 Feb 12, 2019	BUY	$80.14 - $106.07 $7 Million - $9.27 Million	87,349 Added 105.67%	170,013 $14.3 Million
Q3 2018 Nov 09, 2018	BUY	$93.92 - $105.72 $948,404 - $1.07 Million	10,098 Added 13.92%	82,664 $0
Q2 2018 Aug 14, 2018	SELL	$76.01 - $99.03 $3.73 Million - $4.86 Million	-49,059 Reduced 40.34%	72,566 $6.71 Million
Q1 2018 May 03, 2018	SELL	$77.67 - $92.63 $2.52 Million - $3.01 Million	-32,455 Reduced 21.06%	121,625 $9.77 Million
Q3 2017 Nov 06, 2017	BUY	$80.6 - $94.95 $12.4 Million - $14.6 Million	154,080	154,080 $12.9 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.

Account

Deka Bank Deutsche Girozentrale Biomarin Pharmaceutical Inc Transaction History